On April 16 and April 17, Axinn partner Lisl Dunlop will speak on the "Deal Uncertainty – New Antitrust Challenges in Federal Merger Reviews" panel at the American Health Law Association's Health Care Transactions Program, being held April 15-17 in Nashville.

As federal antitrust agencies are continuing to challenge health care transactions aggressively under an ever-broadening range of theories, panelists will discuss key changes in approach including:

• Expanded theories of harm and more stringent review thresholds under the FTC and DOJ 2023 Merger Guidelines;
• Focus on private equity transactions and labor market impacts;
• Potential changes to HSR prenotification regime;
• Agency resistance to remedies to address competitive concerns and;
• Ongoing agency investigations and studies into health care markets.

Click here for more information, including how to register.